June 2024
1. 
   Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73).
   BMJ. 2024;385:q1450.
   

   >> Share

   
   
2. CONRAD N, Molenberghs G, Verbeke G, Zaccardi F, et al
   Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study.
   BMJ. 2024;385:e078523.
   

   >> Share

   
   
3. ZHU Y, Zhang W, Dimagli A, Han L, et al
   Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial.
   BMJ. 2024;385:e075707.
   

   >> Share

   
   
4. SANDNER S
   Dual antiplatelet therapy after coronary artery bypass surgery.
   BMJ. 2024;385:q1083.
   

   >> Share

   
   
5. 
   Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
   BMJ. 2024;385:q1237.
   

   >> Share

   
   May 2024
6. DYER C
   Former cardiovascular surgery lead is charged with 14 counts of sexual assault.
   BMJ. 2024;385:q1188.
   

   >> Share

   
   
7. 
   Cardiovascular toxicity of immune therapies for cancer.
   BMJ. 2024;385:q1197.
   

   >> Share

   
   
8. 
   Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
   BMJ. 2024;385:q1094.
   

   >> Share

   
   
9. PALASKAS NL, Ali HJ, Koutroumpakis E, Ganatra S, et al
   Cardiovascular toxicity of immune therapies for cancer.
   BMJ. 2024;385:e075859.
   

   >> Share

   
   
10. LI Z, Min XW, He PG, Zhang CH, et al
    Chest pain with diffuse ST segment elevation.
    BMJ. 2024;385:e078403.
    

    >> Share

    
    April 2024
11. SIMMS-WILLIAMS N, Treves N, Yin H, Lu S, et al
    Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
    BMJ. 2024;385:e078242.
    

    >> Share

    
    
12. MOK PLH, Carr MJ, Guthrie B, Morales DR, et al
    Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.
    BMJ. 2024;385:e076268.
    

    >> Share

    
    
13. VINTER N, Cordsen P, Johnsen SP, Staerk L, et al
    Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study.
    BMJ. 2024;385:e077209.
    

    >> Share

    
    March 2024
14. WONDERLING D, Mariani A, Samarasekera EJ, Wilkinson C, et al
    Secondary prevention of cardiovascular disease, including cholesterol targets: summary of updated NICE guidance.
    BMJ. 2024;384:q637.
    

    >> Share

    
    
15. SAUL H, Deeney B, Swaithes L, Hounkpatin H, et al
    Even short periods of diabetes remission are linked to lower risk of heart attack and stroke.
    BMJ. 2024;384:q516.
    

    >> Share

    
    
16. TANNE JH
    Wegovy: FDA approves weight loss drug to cut cardiovascular risk.
    BMJ. 2024;384:q642.
    

    >> Share

    
    February 2024
17. 
    Exposure-response associations between chronic exposure to fine particulate matter and risks of hospital admission for major cardiovascular diseases: population based cohort study.
    BMJ. 2024;384:q517.
    

    >> Share

    
    
18. WEI Y, Feng Y, Danesh Yazdi M, Yin K, et al
    Exposure-response associations between chronic exposure to fine particulate matter and risks of hospital admission for major cardiovascular diseases: population based cohort study.
    BMJ. 2024;384:e076939.
    

    >> Share

    
    
19. SUN Y, Milando CW, Spangler KR, Wei Y, et al
    Short term exposure to low level ambient fine particulate matter and natural cause, cardiovascular, and respiratory morbidity among US adults with health insurance: case time series study.
    BMJ. 2024;384:e076322.
    

    >> Share

    
    
20. KIM KS, Hong S, Han K, Park CY, et al
    Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study.
    BMJ. 2024;384:e076388.
    

    >> Share

    
    
21. MAHASE E
    Variability in blood pressure could help predict heart attack and stroke risk, researchers say.
    BMJ. 2024;384:q363.
    

    >> Share

    
    January 2024
22. WISE J
    Early deaths from cardiovascular disease reach 14 year high in England.
    BMJ. 2024;384:q176.
    

    >> Share

    
    
23. PHIZACKERLEY D
    Semaglutide reduces the absolute risk of major cardiovascular events by 1.5.
    BMJ. 2024;384:q53.
    

    >> Share

    
    December 2023
24. KMIETOWICZ Z
    NICE lowers cholesterol target for people with cardiovascular disease.
    BMJ. 2023;383:p2946.
    

    >> Share

    
    November 2023
25. GEBRE AK, Sim M, Schultz C
    Do high sensitivity cardiac troponin assays improve patient outcomes?
    BMJ. 2023;383:2741.
    

    >> Share

    
    
26. LEE KK, Doudesis D, Ferry AV, Chapman AR, et al
    Implementation of a high sensitivity cardiac troponin I assay and risk of myocardial infarction or death at five years: observational analysis of a stepped wedge, cluster randomised controlled trial.
    BMJ. 2023;383:e075009.
    

    >> Share

    
    
27. KHAN SU, Agarwal S, Arshad HB, Akbar UA, et al
    Intravascular imaging guided versus coronary angiography guided percutaneous coronary intervention: systematic review and meta-analysis.
    BMJ. 2023;383:e077848.
    

    >> Share

    
    
28. WISE J
    Semaglutide reduces risk of major cardiovascular events by 20%, finds study.
    BMJ. 2023;383:p2668.
    

    >> Share

    
    October 2023
29. LEE YJ, Hong SJ, Kang WC, Hong BK, et al
    Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial.
    BMJ. 2023;383:e075837.
    

    >> Share

    
    September 2023
30. HUANG WC, Yang AS, Tsai DH, Shao SC, et al
    Association between recently raised anticholinergic burden and risk of acute cardiovascular events: nationwide case-case-time-control study.
    BMJ. 2023;382:e076045.
    

    >> Share

    
    
31. TSAI TY, Loh CH, Huang HK
    Anticholinergic medicines linked to cardiovascular events in older adults.
    BMJ. 2023;382:p2133.
    

    >> Share

    
    
32. SELLEM L, Srour B, Javaux G, Chazelas E, et al
    Food additive emulsifiers and risk of cardiovascular disease in the NutriNet-Sante cohort: prospective cohort study.
    BMJ. 2023;382:e076058.
    

    >> Share

    
    August 2023
33. RAU STEUERNAGEL C, Lam CSP, Greenhalgh T
    Countering sex and gender bias in cardiovascular research requires more than equal recruitment and sex disaggregated analyses.
    BMJ. 2023;382:e075031.
    

    >> Share

    
    
34. STURMBERG J
    Study results show vitamin D is around 99% ineffective in preventing major cardiovascular events.
    BMJ. 2023;382:p1767.
    

    >> Share

    
    
35. SATTAR N
    There is no evidence that vitamin D prevents cardiovascular events.
    BMJ. 2023;382:p1765.
    

    >> Share

    
    July 2023
36. RALEIGH V, Colombo F
    Cardiovascular disease should be a priority for health systems globally.
    BMJ. 2023;382:e076576.
    

    >> Share

    
    
37. BEERSTECHER HJ
    NICE guidance on cardiovascular disease risk assessment and reduction is disappointing.
    BMJ. 2023;382:p1506.
    

    >> Share

    
    
38. SUMMERS DJ
    Cardiovascular disease: what does QRISK actually measure?
    BMJ. 2023;382:1502.
    

    >> Share

    
    June 2023
39. THOMPSON B, Waterhouse M, English DR, McLeod DS, et al
    Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial.
    BMJ. 2023;381:e075230.
    

    >> Share

    
    
40. GALE CP, Stocken DD, Aktaa S, Reynolds C, et al
    Effectiveness of GRACE risk score in patients admitted to hospital with non-ST elevation acute coronary syndrome (UKGRIS): parallel group cluster randomised controlled trial.
    BMJ. 2023;381:e073843.
    

    >> Share

    
    May 2023
41. SAMARASEKERA EJ, Clark CE, Kaur S, Patel RS, et al
    Cardiovascular disease risk assessment and reduction: summary of updated NICE guidance.
    BMJ. 2023;381:1028.
    

    >> Share

    
    March 2023
42. KARAM G, Agarwal A, Sadeghirad B, Jalink M, et al
    Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: systematic review and network meta-analysis.
    BMJ. 2023;380:e072003.
    

    >> Share

    
    
43. MORALES DR, Minchin M, Kontopantelis E, Roland M, et al
    Estimated impact from the withdrawal of primary care financial incentives on selected indicators of quality of care in Scotland: controlled interrupted time series analysis.
    BMJ. 2023;380:e072098.
    

    >> Share

    
    
44. LITTLE MP, Azizova TV, Richardson DB, Tapio S, et al
    Ionising radiation and cardiovascular disease: systematic review and meta-analysis.
    BMJ. 2023;380:e072924.
    

    >> Share

    
    
45. AUVINEN A
    Increased cardiovascular disease risk after exposure to low dose radiation.
    BMJ. 2023;380:e074589.
    

    >> Share

    
    February 2023
46. CRUMP C, Sundquist J, McLaughlin MA, Dolan SM, et al
    Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: national cohort and co-sibling study.
    BMJ. 2023;380:e072112.
    

    >> Share

    
    January 2023
47. O'DOWD A
    NICE recommends wider use of statins to cut cardiovascular risk.
    BMJ. 2023;380:p89.
    

    >> Share

    
    October 2022
48. 
    Comparative effectiveness of initial computed tomography and invasive coronary angiography in women and men with stable chest pain and suspected coronary artery disease: multicentre randomised trial.
    BMJ. 2022;379:e071133.
    

    >> Share

    
    September 2022
49. XIE W, Wang Y, Xiao S, Qiu L, et al
    Association of gestational diabetes mellitus with overall and type specific cardiovascular and cerebrovascular diseases: systematic review and meta-analysis.
    BMJ. 2022;378:e070244.
    

    >> Share

    
    
50. YUN I
    Regional inequality in myocardial infarction treatment cannot be blamed on effectiveness of individual cardiologists.
    BMJ. 2022;378:o2235.
    

    >> Share

    
    
51. DEBRAS C, Chazelas E, Sellem L, Porcher R, et al
    Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Sante cohort.
    BMJ. 2022;378:e071204.
    

    >> Share

    
    June 2022
52. WISE J
    NICE endorses new drug to prevent myocardial infarctions and strokes.
    BMJ. 2022;377:o1444.
    

    >> Share

    
    
53. AL-LAMEE RK, Foley M, Rajkumar CA, Francis DP, et al
    Revascularization in stable coronary artery disease.
    BMJ. 2022;377:e067085.
    

    >> Share

    
    May 2022
54. LU Y, Melnick ER, Krumholz HM
    Clinical decision support in cardiovascular medicine.
    BMJ. 2022;377:e059818.
    

    >> Share

    
    
55. 
    Variation in revascularisation use and outcomes of patients in hospital with acute myocardial infarction across six high income countries: cross sectional cohort study.
    BMJ. 2022;377:o1161.
    

    >> Share

    
    
56. CRAM P, Hatfield LA, Bakx P, Banerjee A, et al
    Variation in revascularisation use and outcomes of patients in hospital with acute myocardial infarction across six high income countries: cross sectional cohort study.
    BMJ. 2022;377:e069164.
    

    >> Share

    
    
57. KHAN SU, Yedlapati SH, Lone AN, Hao Q, et al
    PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
    BMJ. 2022;377:e069116.
    

    >> Share

    
    
58. HAO Q, Aertgeerts B, Guyatt G, Bekkering GE, et al
    PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    BMJ. 2022;377:e069066.
    

    >> Share

    
    April 2022
59. HARSKAMP RE, Fanaroff AC, Zhen SW, Sawe HR, et al
    Recognising acute coronary syndrome.
    BMJ. 2022;377:e069591.
    

    >> Share

    
    March 2022
60. HODKINSON A, Tsimpida D, Kontopantelis E, Rutter MK, et al
    Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis.
    BMJ. 2022;376:e067731.
    

    >> Share

    
    
61. MAHASE E
    Study questions relationship between statins and cardiovascular outcomes.
    BMJ. 2022;376:o712.
    

    >> Share

    
    February 2022
62. 
    Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial.
    BMJ. 2022;376:o438.
    

    >> Share

    
    
63. TANNE JH
    Six in 10 US women have poor cardiovascular health before pregnancy, study finds.
    BMJ. 2022;376:o402.
    

    >> Share

    
    January 2022
64. 
    P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.
    BMJ. 2022;376:o239.
    

    >> Share

    
    
65. BRUSH JE JR, Sherbino J, Norman GR
    Diagnostic reasoning in cardiovascular medicine.
    BMJ. 2022;376:e064389.
    

    >> Share

    
    November 2021
66. FU EL, Evans M, Carrero JJ, Putter H, et al
    Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study.
    BMJ. 2021;375:e066306.
    

    >> Share

    
    
67. BELTRAME JF, Tavella R, Jones D, Zeitz C, et al
    Management of ischaemia with non-obstructive coronary arteries (INOCA).
    BMJ. 2021;375:e060602.
    

    >> Share

    
    
68. SAUL H, Gursul D
    Even low doses of steroids increase the risk of cardiovascular disease in people with inflammatory diseases.
    BMJ. 2021;375:n2599.
    

    >> Share

    
    October 2021
69. MAHASE E
    US taskforce advises against low dose aspirin for primary prevention of cardiovascular disease.
    BMJ. 2021;375:n2521.
    

    >> Share

    
    
70. NAGHSHI S, Aune D, Beyene J, Mobarak S, et al
    Dietary intake and biomarkers of alpha linolenic acid and risk of all cause, cardiovascular, and cancer mortality: systematic review and dose-response meta-analysis of cohort studies.
    BMJ. 2021;375:n2213.
    

    >> Share

    
    September 2021
71. GRAY AJ, Roobottom C, Smith JE, Goodacre S, et al
    Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial.
    BMJ. 2021;374:n2106.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share